Zaloguj się

Gotowe bibliografie tematyczne / Tumstatin / Artykuły w czasopismach

Artykuły w czasopismach na temat „Tumstatin”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Tumstatin.

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 21 lutego 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Tumstatin”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Wang, Shu Jing, Jia Liu, Fei Wang, Ning Chen, Shan Jiang, Lin Liu, Ying Zhao i Xiao Dan Zhang. "Tumstatin 7 Peptide Affect Biological Activity of B16 Melanoma Cell". Advanced Materials Research 641-642 (styczeń 2013): 915–18. http://dx.doi.org/10.4028/www.scientific.net/amr.641-642.915.

Pełny tekst źródła

Streszczenie:

To study the effect of biological activity of Tumstatin 7 peptide on the cell proliferation and apoptosis of B16 melanoma. Tumstatin 7 peptide was synthesized and its purity is 98.4532% by high-performance liquid chromatography. The effect of 7 peptide on B16 melanoma was observed by MTT, cell growth curve, the observation of the transmission electron microscope (TEM). 7 peptide can significantly inhibit B16 melanoma cell proliferation, showing dose- and time-dependent .Its IC50 was 72.53 μg/ml.The morphology of B16 melanoma cell was obviously changed by TEM, such as karyopyknosis and apoptotic bodies. So7 peptides can inhibit the proliferation of melanoma cells and promote melanoma cells apoptosis. It will be of great potential value to melanoma treatment.

Style APA, Harvard, Vancouver, ISO itp.

2

Bonn, Dorothy. "Tumstatin hints at how angiogenesis inhibitors work". Lancet Oncology 3, nr 2 (luty 2002): 71. http://dx.doi.org/10.1016/s1470-2045(02)00641-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

WANG, WEI, CHUN-XIAO XU, GUO-SHENG HOU, YOU-GEN CHEN, JIA-XUAN XIN i XIAN-XI LIU. "Downregulation of tumstatin expression by overexpression of ornithine decarboxylase". Oncology Reports 30, nr 5 (29.08.2013): 2042–48. http://dx.doi.org/10.3892/or.2013.2708.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Maeshima, Y. "Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis". Science 295, nr 5552 (4.01.2002): 140–43. http://dx.doi.org/10.1126/science.1065298.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Oruc, Y., i S. Aydin. "Blood and aqueous humor tumstatin concentrations associated with diabetic retinopathy". Annals of Systems Biology 3, nr 1 (25.04.2020): 025–28. http://dx.doi.org/10.17352/asb.000008.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Nissen, Gyde, Henrike Hollaender, Francesca S. M. Tang, Michael Wegmann, Lars Lunding, Christina Vock, Anna Bachmann i in. "Tumstatin fragment selectively inhibits neutrophil infiltration in experimental asthma exacerbation". Clinical & Experimental Allergy 48, nr 11 (28.08.2018): 1483–93. http://dx.doi.org/10.1111/cea.13236.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Gu, Quliang, Tianyuan Zhang, Jinxian Luo i Fangyu Wang. "Expression, purification, and bioactivity of human tumstatin from Escherichia coli". Protein Expression and Purification 47, nr 2 (czerwiec 2006): 461–66. http://dx.doi.org/10.1016/j.pep.2006.01.011.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Caudroy, Stephanie, Joel Cucherousset, Marianne Lorenzato, Jean-Marie Zahm, Corinne Martinella-Catusse, Myriam Polette i Philippe Birembaut. "Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas". Human Pathology 35, nr 10 (październik 2004): 1218–22. http://dx.doi.org/10.1016/j.humpath.2004.06.008.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Xu, Chun-xiao, Xian-xi Liu, Guo-sheng Hou, Yun-fei Yan, Shi-min Chen, Wei Wang, Guang-shui Jiang, Bin Liu i Jia-xuan Xin. "The expression of tumstatin is down-regulated in renal carcinoma". Molecular Biology Reports 37, nr 5 (18.08.2009): 2273–77. http://dx.doi.org/10.1007/s11033-009-9718-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Wei, C., A. Y. Xun, X. X. Wei, J. Yao, J. Y. Wang, R. Y. Shi, G. H. Yang i in. "BifidobacteriaExpressing Tumstatin Protein for Antitumor Therapy in Tumor-Bearing Mice". Technology in Cancer Research & Treatment 15, nr 3 (11.05.2015): 498–508. http://dx.doi.org/10.1177/1533034615581977.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Wang, Shu Jing, Ning Chen, Zhang Yi, Jia Liu i Bei Bei Xu. "Study on the Biological Activity of Anti-Tumor Peptide of Tumstatin". Advanced Materials Research 183-185 (styczeń 2011): 1509–12. http://dx.doi.org/10.4028/www.scientific.net/amr.183-185.1509.

Pełny tekst źródła

Streszczenie:

Tumstatin anti-tumor peptide of 19peptide can inhibit the proliferation of melanoma cell. To study its effect on the proliferation and apoptosis of different tumor cells and verify its anti-tumor non-specificity, the base sequence of 19peptide was designed and constructed engineering bacteria. The soluble 19peptide was obtained from one step chitin affinity chromatograph. By such experiment as MTT assay, cell growth curve, TUNEL assay，flow cytometry，transmission electron microscopy(TEM), the biological activity of 19peptide was studied. Experiments in vitro identified that obtained 19peptide could inhibit proliferation of hela cell and hepatocarcinoma cell. It also could promote two tumor cells apoptosis. Its anti-tumor effect will lay foundation on its mechanism of action research and clinically tumor therapy in future.

Style APA, Harvard, Vancouver, ISO itp.

12

Thevenard, Jessica, Nicolas Floquet, Laurent Ramont, Elise Prost, Jean-Marc Nuzillard, Manuel Dauchez, Hocine Yezid i in. "Structural and Antitumor Properties of the YSNSG Cyclopeptide Derived from Tumstatin". Chemistry & Biology 13, nr 12 (grudzień 2006): 1307–15. http://dx.doi.org/10.1016/j.chembiol.2006.10.007.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Wang, Shujing, Yan Liu, Xuesong Lin, Xue Fu, Jianyong Xu i Xinghan Liu. "Cloning and biological activity of an anti-tumor peptide of Tumstatin". Frontiers of Biology in China 2, nr 3 (lipiec 2007): 276–83. http://dx.doi.org/10.1007/s11515-007-0040-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Luo, Yi-Qin, Liang-Hua Wang, Qui Yi i Bing-Hua Jiao. "Expression of soluble, biologically active recombinant human tumstatin in Escherichia coli". Clinical and Experimental Medicine 8, nr 1 (marzec 2008): 37–42. http://dx.doi.org/10.1007/s10238-008-0154-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Burgess, Janette K., Sarah Boustany, Lyn M. Moir, Markus Weckmann, Justine Y. Lau, Karryn Grafton, Melissa Baraket i in. "Reduction of Tumstatin in Asthmatic Airways Contributes to Angiogenesis, Inflammation, and Hyperresponsiveness". American Journal of Respiratory and Critical Care Medicine 181, nr 2 (15.01.2010): 106–15. http://dx.doi.org/10.1164/rccm.200904-0631oc.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Zhang, Pengguo, Qingwei Zhou, Lin Tian, Xiangyu Zhou, Yue Zhou i Jiajun Chen. "Experimental study of a novel tumstatin on C6 brain glioma in vitro". Oncology Letters 14, nr 3 (30.06.2017): 2845–51. http://dx.doi.org/10.3892/ol.2017.6507.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Maeshima, Yohei, Mark Manfredi, Corinne Reimer, Kathryn A. Holthaus, Helmut Hopfer, Babi R. Chandamuri, Surender Kharbanda i Raghu Kalluri. "Identification of the Anti-angiogenic Site within Vascular Basement Membrane-derived Tumstatin". Journal of Biological Chemistry 276, nr 18 (7.02.2001): 15240–48. http://dx.doi.org/10.1074/jbc.m007764200.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Luo, Yi-Qin, Zhou Ming, Liang Zhao, Li-Juan Yao, Hang Dong, Jian-Ping Du, Shuang-Zheng Wu i Wen Hu. "Decreased tumstatin-mRNA is associated with poor outcome in patients with NSCLC". IUBMB Life 64, nr 5 (31.03.2012): 423–31. http://dx.doi.org/10.1002/iub.1016.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Li, Juan, Jing Luo, Yi-Qin Luo, Ming Zhou, Liang Zhao, Li-Juan Yao, Hang Dong i Rui-Ning Yang. "Overexpression of tumstatin in genetically modified megakaryocytes changes the proangiogenic effect of platelets". Transfusion 54, nr 8 (24.03.2014): 2106–17. http://dx.doi.org/10.1111/trf.12617.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Li, Ying-jie, Li-chun Sun, Yan He, Xing-han Liu, Miao Liu, Qi-min Wang i Xiao-ming Jin. "The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma". Acta Pharmacologica Sinica 30, nr 9 (24.08.2009): 1307–15. http://dx.doi.org/10.1038/aps.2009.111.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Yasuda, Jumpei, Muneyoshi Okada i Hideyuki Yamawaki. "T3 peptide, a fragment of tumstatin, prevents the ischemia-reperfusion injury in cardiomyocytes". Proceedings for Annual Meeting of The Japanese Pharmacological Society WCP2018 (2018): PO1–2–65. http://dx.doi.org/10.1254/jpssuppl.wcp2018.0_po1-2-65.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Sun, Chao, Dongyang He, Chao Ma, Zhenyue Gao, Yijun Chen i Shuzhen Wang. "Bifunctional Fusion Proteins Derived from Tumstatin and 4-1BBL for Targeted Cancer Therapy". Molecular Pharmaceutics 16, nr 2 (19.12.2018): 867–76. http://dx.doi.org/10.1021/acs.molpharmaceut.8b01190.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Harkness, Louise Margaret, Markus Weckmann, Matthias Kopp, Tim Becker, Anthony Wayne Ashton i Janette Kay Burgess. "Tumstatin regulates the angiogenic and inflammatory potential of airway smooth muscle extracellular matrix". Journal of Cellular and Molecular Medicine 21, nr 12 (13.06.2017): 3288–97. http://dx.doi.org/10.1111/jcmm.13232.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Maeshima, Yohei, Pablo C. Colorado i Raghu Kalluri. "Two RGD-independent αvβ3Integrin Binding Sites on Tumstatin Regulate Distinct Anti-tumor Properties". Journal of Biological Chemistry 275, nr 31 (2.06.2000): 23745–50. http://dx.doi.org/10.1074/jbc.c000186200.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Gu, Quliang, Cihuang Sun, Jinxian Luo, Tianyuan Zhang i Lijing Wang. "Inhibition of angiogenesis by a synthetic fusion protein VTF derived from vasostatin and tumstatin". Anti-Cancer Drugs 25, nr 9 (październik 2014): 1044–51. http://dx.doi.org/10.1097/cad.0000000000000134.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Zan, Jinhang, Xin He, Wei Long i Peixun Liu. "Insights into binding modes of tumstatin peptide T7 with the active site of αvβ3integrin". Molecular Simulation 38, nr 6 (maj 2012): 498–508. http://dx.doi.org/10.1080/08927022.2011.649428.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Naling, Song, He Xin, Zhao Qiren, Yan Tingdong i Wen Lei. "Cloning and expression of the tumstatin active peptides-T7 and its derivant-T7-NGR". Clinical and Experimental Medicine 9, nr 2 (3.02.2009): 165–71. http://dx.doi.org/10.1007/s10238-008-0029-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Wang, Shu Jing, Shan Jiang, Jia Liu, Fei Wang, Ning Chen, Lin Liu, Ying Zhao i Xiao Dan Zhang. "The Effect of T-7 Peptide on Human Non-Small-Cell Carcinoma A549 Cells". Advanced Materials Research 641-642 (styczeń 2013): 820–23. http://dx.doi.org/10.4028/www.scientific.net/amr.641-642.820.

Pełny tekst źródła

Streszczenie:

7 peptide of Tumstatin(T-7 peptide) is composed of 185-191 amino acids. To study T-7 peptide antitumor activity to human non-small-cell carcinoma(A549), T-7 peptide was designed and synthesized by amino acid synthesizer. Its purity ran up to 98.45% by HPLC and MS. The effect of T-7 peptide on A549 cell growth was observed by MTT assay, growth curve and transmission electron microscopy(TEM). T-7 peptide had the effects of suppressing A549 cell growth and promoting its apoptosis, showing dose- and time-dependent. Its IC50 was 92.84 μg/ml. TEM also revealed that A549 cell treated with T-7 peptide appeared apoptotic morphology,such as cell pyknosis and mitochondrial vacuoles formed. While T-7 peptide had little effect on human umbilical vein endothelial cells(ECV304). These researches were significant to treat human non-small-cell carcinoma in the future.

Style APA, Harvard, Vancouver, ISO itp.

29

Wang, Shu Jing, Fei Wang, Jia Liu, Shan Jiang, Ning Chen, Lin Liu, Ying Zhao i Xiao Dan Zhang. "Effect of Tumstatin T-7 Peptide on HepG-2 Cells and Human Umbilical Vein Endothelial Cells". Advanced Materials Research 641-642 (styczeń 2013): 744–47. http://dx.doi.org/10.4028/www.scientific.net/amr.641-642.744.

Pełny tekst źródła

Streszczenie:

The direct anti-tumor T-7 peptide of tumstatin was obtained to study its effect on human hepatoma cells (HepG-2) and human umbilical vein endothelial cells (ECV304). T-7 peptide was synthesized and its purity was up to 98.5%. MTT assay, growth curve, transmission electron microscopy(TEM) were used to detect the proliferation inhibition and pro-apoptotic function. MTT experiments and growth curve experiments showed that the survival of human hepatoma cells (HepG-2) decreased in a time- and dose-dependent way with the concentration of T-7 peptide increased. T-7 peptide can induce apoptosis of HepG-2 significantly. Apoptosis features were observed by TEM. However, the inhibition of T-7 peptide on human umbilical vein endothelial cells (ECV304) was weaker. Experiments showed thatT-7 peptide can affect HepG-2 cells. It had a certain therapeutic effect on human hepatocellular carcinoma. T-7 peptide have little effect on ECV304 cells, which means it didn’t influence the formation of tumor angiogenesis and normal cells

Style APA, Harvard, Vancouver, ISO itp.

30

S Boosani, Chandra, Ashok K Verma i Akulapalli Sudhakar. "Validation of Different Systems for Tumstatin Expression and its in-vitro and iv-vivo Activities". Journal of Cancer Science & Therapy 01, nr 01 (2009): 008–18. http://dx.doi.org/10.4172/1948-5956.1000002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Yao, Bin, Qiu-Ming He, Ling Tian, Fei Xiao, Yu Jiang, Ru Zhang, Gang Li i in. "Enhanced Antitumor Effect of the Combination of Tumstatin Gene Therapy and Gemcitabine in Murine Models". Human Gene Therapy 16, nr 9 (wrzesień 2005): 1075–86. http://dx.doi.org/10.1089/hum.2005.16.1075.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Sun, Chao, Dongyang He, Chao Ma, Zhenyue Gao, Yijun Chen i Shuzhen Wang. "Correction to “Bifunctional Fusion Proteins Derived from Tumstatin and 4–1BBL for Targeted Cancer Therapy”". Molecular Pharmaceutics 16, nr 12 (14.11.2019): 5085. http://dx.doi.org/10.1021/acs.molpharmaceut.9b01144.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Chang, Kyung Hwa, Jong Min Lee, Hee Kyoung Jeon i In Sik Chung. "Improved production of recombinant tumstatin in stably transformed Trichoplusia ni BTI Tn 5B1-4 cells". Protein Expression and Purification 35, nr 1 (maj 2004): 69–75. http://dx.doi.org/10.1016/j.pep.2004.01.004.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

Esipov, Roman, Ksenia Beyrakhova, Vera Likhvantseva, Evgenia Stepanova, Vasily Stepanenko, Maria Kostromina, Yulia Abramchik i Anatoly Miroshnikov. "Antiangiogenic and antivascular effects of a recombinant tumstatin-derived peptide in a corneal neovascularization model". Biochimie 94, nr 6 (czerwiec 2012): 1368–75. http://dx.doi.org/10.1016/j.biochi.2012.03.007.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

REN, Na, Liang-hua WANG, Yun GAO, Ming-juan SUN, Yu-liang JIAO, Ai-yun GUO i Bing-hua JIAO. "Expression of Tumstatin_183-230-TRAIL fusion protein and identification of its biological functions". Academic Journal of Second Military Medical University 28, nr 5 (13.10.2008): 474–78. http://dx.doi.org/10.3724/sp.j.1008.2008.00474.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

WANG, YANG, RUO-FENG YIN i JIA-SONG TENG. "Tumstatin induces apoptosis and stimulates phosphorylation of p65NF-κB in human osteoblastic osteosarcoma Saos-2 cells". Oncology Reports 35, nr 6 (20.04.2016): 3403–8. http://dx.doi.org/10.3892/or.2016.4762.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Yamamoto, Y., Y. Maeshima, H. Kitayama, S. Kitamura, Y. Takazawa, H. Sugiyama, Y. Yamasaki i H. Makino. "Tumstatin Peptide, an Inhibitor of Angiogenesis, Prevents Glomerular Hypertrophy in the Early Stage of Diabetic Nephropathy". Diabetes 53, nr 7 (25.06.2004): 1831–40. http://dx.doi.org/10.2337/diabetes.53.7.1831.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Folkman, J. "Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin". Science's STKE 2006, nr 354 (19.09.2006): pe35. http://dx.doi.org/10.1126/stke.3542006pe35.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Thevenard, Jessica, Laurent Ramont, Lluis M. Mir, Aurélie Dupont-Deshorgue, François-Xavier Maquart, Jean-Claude Monboisse i Sylvie Brassart-Pasco. "A new anti-tumor strategy based on in vivo tumstatin overexpression after plasmid electrotransfer in muscle". Biochemical and Biophysical Research Communications 432, nr 4 (marzec 2013): 549–52. http://dx.doi.org/10.1016/j.bbrc.2013.02.074.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

HWANG-BO, JEON, JONG-HWA PARK i IN SIK CHUNG. "Tumstatin induces apoptosis mediated by Fas signaling pathway in oral squamous cell carcinoma SCC-VII cells". Oncology Letters 10, nr 2 (25.05.2015): 1016–22. http://dx.doi.org/10.3892/ol.2015.3261.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

ZHANG, Guang-mei, Ying-mei ZHANG, Song-bin FU, Xing-han LIU, Xue FU, Yan YU i Zhi-yi ZHANG. "Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells". Chinese Medical Journal 121, nr 22 (listopad 2008): 2324–30. http://dx.doi.org/10.1097/00029330-200811020-00020.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Tanabe, Katsuyuki, Yohei Maeshima, Yasufumi Sato i Jun Wada. "Antiangiogenic Therapy for Diabetic Nephropathy". BioMed Research International 2017 (2017): 1–12. http://dx.doi.org/10.1155/2017/5724069.

Pełny tekst źródła

Streszczenie:

Angiogenesis has been shown to be a potential therapeutic target for early stages of diabetic nephropathy in a number of animal experiments. Vascular endothelial growth factor (VEGF) is the main mediator for abnormal angiogenesis in diabetic glomeruli. Although beneficial effects of anti-VEGF antibodies have previously been demonstrated in diabetic animal experiments, recent basic and clinical evidence has revealed that the blockade of VEGF signaling resulted in proteinuria and renal thrombotic microangiopathy, suggesting the importance of maintaining normal levels of VEGF in the kidneys. Therefore, antiangiogenic therapy for diabetic nephropathy should eliminate excessive glomerular angiogenic response without accelerating endothelial injury. Some endogenous antiangiogenic factors such as endostatin and tumstatin inhibit overactivation of endothelial cells but do not specifically block VEGF signaling. In addition, the novel endothelium-derived antiangiogenic factor vasohibin-1 enhances stress tolerance and survival of the endothelial cells, while inhibiting excess angiogenesis. These factors have been demonstrated to suppress albuminuria and glomerular alterations in a diabetic mouse model. Thus, antiangiogenic therapy with promising candidates will possibly improve renal prognosis in patients with early stages of diabetic nephropathy.

Style APA, Harvard, Vancouver, ISO itp.

43

Sudhakar, Akulapalli, i Chandra S. Boosani. "Retraction Note: Inhibition of Tumor Angiogenesis by Tumstatin: Insights into Signaling Mechanisms and Implications in Cancer Regression". Pharmaceutical Research 38, nr 2 (15.01.2021): 377. http://dx.doi.org/10.1007/s11095-020-02974-x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

He, Yan, Yang Jiang, Ying-Jie Li, Xing-Han Liu, Lei Zhang, Li-Juan Liu, Hang Shi, Hui-Ning Li, Yong-Cu Ma i Xiao-Ming Jin. "19-peptide, a fragment of tumstatin, inhibits the growth of poorly differentiated gastric carcinoma cellsin vitroandin vivo". Journal of Gastroenterology and Hepatology 25, nr 5 (28.04.2010): 935–41. http://dx.doi.org/10.1111/j.1440-1746.2009.06209.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Sudhakar, A., H. Sugimoto, C. Yang, J. Lively, M. Zeisberg i R. Kalluri. "Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by v 3 and 5 1 integrins". Proceedings of the National Academy of Sciences 100, nr 8 (7.04.2003): 4766–71. http://dx.doi.org/10.1073/pnas.0730882100.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Yasuda, Jumpei, Muneyoshi Okada i Hideyuki Yamawaki. "Protective effect of T3 peptide, an active fragment of tumstatin, against ischemia/reperfusion injury in rat heart". Journal of Pharmacological Sciences 139, nr 3 (marzec 2019): 193–200. http://dx.doi.org/10.1016/j.jphs.2019.01.010.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Yasuda, Jumpei, Muneyoshi Okada i Hideyuki Yamawaki. "T3 peptide, an active fragment of tumstatin, inhibits H 2 O 2 -induced apoptosis in H9c2 cardiomyoblasts". European Journal of Pharmacology 807 (lipiec 2017): 64–70. http://dx.doi.org/10.1016/j.ejphar.2017.04.032.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Pasco, Sylvie, Laurent Ramont, Lydie Venteo, Michel Pluot, François-Xavier Maquart i Jean-Claude Monboisse. "In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model". Experimental Cell Research 301, nr 2 (grudzień 2004): 251–65. http://dx.doi.org/10.1016/j.yexcr.2004.07.036.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Eikesdal, H. P., H. Sugimoto, G. Birrane, Y. Maeshima, V. G. Cooke, M. Kieran i R. Kalluri. "Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity". Proceedings of the National Academy of Sciences 105, nr 39 (25.09.2008): 15040–45. http://dx.doi.org/10.1073/pnas.0807055105.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Yu, Wei, Jun'an Hu, Haiwei Le, Yigao Lu, Weihua Xu, Wangfang Yu i Wei Shen. "Tumstatin attenuates the promotion effect of IL-17 secreted by Th17 cells on the stemness maintenance of glioma cells". Pathology - Research and Practice 223 (lipiec 2021): 153463. http://dx.doi.org/10.1016/j.prp.2021.153463.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!